Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases

• DOI: 10.1007/bf01650510
• Publication Date: 2005-05-07T17:02:26Z
• Authors: S. Esposito; D. Galante; D. Barba; R. Giusti; W. Bianchi; R. Gagliardi
• Keywords: Adult; Male; Clinical Trials as Topic; 0303 health sciences; Liver Diseases; Bacterial Infections; 3. Good health; 03 medical and health sciences; Ciprofloxacin; Urinary Tract Infections; Humans; Female; Respiratory Tract Infections

The clinical efficacy and the safety of ciprofloxacin was studied in 92 patients (aged 26 to 83 years; mean 57.5 years) affected by urinary tract infections (UTI) and respiratory tract infections (RTI) suffering also with various liver diseases. Ciprofloxacin was given orally at different dose regimens: 500 mg b.i.d. (22 cases), 250 mg b.i.d. (20 cases), 500 mg s.i.d. (20 cases) for the treatment of UTIs; 500 mg b.i.d. (ten cases) and 250 mg b.i.d. (20 cases) for the treatment of RTIs. The doses were not correlated to the severity of the infections. Patients were treated for five to 15 days. All the bacteria isolated from sputum or urine before treatment were sensitive to ciprofloxacin (MIC range less than or equal to 0.015 mg/l to 8 mg/l). The clinical and bacteriological responses were favourable in a high percentage of patients both for RTIs and UTIs, irrespective of the dose. Side effects were infrequent (7%) and mild (nausea, gastralgia, oral candidosis), never requiring the interruption of the treatment. No change in the blood chemistry tests was observed at any dose.